That was the question posed to me recently by Lisa McKenzie, a smart, vibrant woman – and fiercely good writer – who suffers from relapsing remitting multiple sclerosis. She explores this question in her blog, mslabrat.com, which chronicles her journey through a pharmaceutical wilderness, and her switch from an FDA-approved therapy to an off-label drug.
She was horrified to learn of what actually goes on in our drug supply, a topic taken up today by the U.S. Senate Committee on Health, Education, Labor and Pensions. So nine years after counterfeit Epogen, four years after tainted Heparin, two years after mishandled insulin harmed American patients, the issue gets another airing in Congress.
Lisa has got some eminently practical ideas for fixing the mess. How about telling patients where their drug came from and what’s in it? For her, it’s personal, a matter of life and death. And she finds the corruption of our drug supply, as laid out in Dangerous Doses, “absolutely terrifying, scarier than any horror flick.” Read her review here.